| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/14/2006 | US20060204565 comprises a folate receptor ligand capable of binding to activated macrophages or a vitamin/vitamin-receptor binding analog and immunogen, a cytotoxin, or another compound capable of altering macrophage function |
| 09/14/2006 | US20060204525 Identifying compounds and methods using compounds which modulate interaction of lethal factor and anthrolysin O |
| 09/14/2006 | US20060204524 Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| 09/14/2006 | US20060204523 Flavivirus vaccine delivery system |
| 09/14/2006 | US20060204522 Immunogenic compositions comprising Lawsonia intracellularis |
| 09/14/2006 | US20060204521 Vector carrying a polynucleotide which encodes a polypeptide having the ability to stimulate an immune response against the polypeptide of Seq ID No:24 |
| 09/14/2006 | US20060204520 Vaccine composition |
| 09/14/2006 | US20060204519 Genetic vaccine for generating immunity to human immunodeficiency virus-1 |
| 09/14/2006 | US20060204516 Compositions and methods for enhancing the immunogenicity of antigens |
| 09/14/2006 | US20060204515 Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi |
| 09/14/2006 | US20060204514 Expression of hydrophobic proteins |
| 09/14/2006 | US20060204513 Novel surface protein (hbsag) variant of the hepatitis b virus |
| 09/14/2006 | US20060204512 Ephrin extracellular domain polypeptides for use in diagnosis prevention and treatment of cell proliferative disorders |
| 09/14/2006 | US20060204511 Use of recombinant or synthetic gelatin as stabiliser in vaccines |
| 09/14/2006 | US20060204510 Bv8 nucleic acids and polypeptides with mitogenic activity |
| 09/14/2006 | US20060204509 Accelerated CD8+ T-cell memory after dendritic cell vaccination |
| 09/14/2006 | US20060204508 Treatment of autoimmune diseases using an activator for the notch signalling pathway |
| 09/14/2006 | US20060204507 Method for generating an immune response and reagents therefor |
| 09/14/2006 | US20060204506 Anti-mesothelin antibodies |
| 09/14/2006 | US20060204505 Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| 09/14/2006 | US20060204504 Reducing leakage from unwanted choroidal neovasculature by administering an anti-FasL factor to permit an effective amount to localize in the neovasculature, administering a photosensitizer to the neovasculature, and irradiating it with laser light; photodynamic therapy |
| 09/14/2006 | US20060204503 Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors |
| 09/14/2006 | US20060204502 Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists |
| 09/14/2006 | US20060204501 Drug for cancer therapy |
| 09/14/2006 | US20060204500 Methods for modulating expression of an HIV-1 fusion cofactor |
| 09/14/2006 | US20060204499 Tumour necrosis factor binding ligands |
| 09/14/2006 | US20060204498 Novel antagonists of cxcr3-binding cxc chemokines |
| 09/14/2006 | US20060204497 Customization of cancer therapy by adminstering modifying antibodies from antigens expressed from cancerous tissue which are cytotoxic to cancer cells while non-toxic to non-cancerous cells; monoclonal antibody antigen binding fragment having identifying characteristics by cloning deposits |
| 09/14/2006 | US20060204496 Agonist antibody against heteroreceptor |
| 09/14/2006 | US20060204495 Isolation and identification of cross-reactive t cells |
| 09/14/2006 | US20060204494 Methionine sulfoxide antibodies |
| 09/14/2006 | US20060204493 Heteromultimeric molecules |
| 09/14/2006 | US20060204492 Compositions and methods for producing enhanced antibodies |
| 09/14/2006 | US20060204483 determining whether a target cell expresses telomerase reverse transcriptase (TRT) by combining human T lymphocytes ex vivo with antigen-presenting cells containing a polypeptide that comprises at least 8 consecutive amino acids of telomerase reverse transcriptase |
| 09/14/2006 | US20060204477 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 09/14/2006 | CA2600905A1 Varicella zoster virus vaccine |
| 09/14/2006 | CA2600836A1 Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| 09/14/2006 | CA2600675A1 Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| 09/14/2006 | CA2600608A1 Composition comprising human igg2 antibody and chelating agent |
| 09/14/2006 | CA2600588A1 Anti-madcam antibody compositions |
| 09/14/2006 | CA2600434A1 Anti-ctla-4 antibody compositions |
| 09/14/2006 | CA2600350A1 Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| 09/14/2006 | CA2600113A1 Pharmaceutical liposomal compositions |
| 09/14/2006 | CA2600036A1 Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
| 09/14/2006 | CA2599697A1 Chemically defined stabiliser composition |
| 09/14/2006 | CA2597485A1 Methods and compositions for modulating tweak and fn14 activity |
| 09/14/2006 | CA2597255A1 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/13/2006 | EP1700868A2 A method for removing an antibody from blood or plasma |
| 09/13/2006 | EP1700606A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 09/13/2006 | EP1700603A2 Immunostimulatory nucleic acids |
| 09/13/2006 | EP1700121A2 Agonist anti-trkc antibodies and methods using same |
| 09/13/2006 | EP1699925A1 Il-23 and its receptor; related reagents and methods |
| 09/13/2006 | EP1699919A1 A respiratory syncytial virus with a genomic deficiency complemented in trans |
| 09/13/2006 | EP1699823A2 Use of il-18 binding protein in inflammations |
| 09/13/2006 | EP1699820A2 Neutralizing epitope-based growth enhancing vaccine |
| 09/13/2006 | EP1699814A2 Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
| 09/13/2006 | EP1699810A2 A beta immunogenic peptide carrier conjugates and methods of producing same |
| 09/13/2006 | EP1699500A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 09/13/2006 | EP1699486A2 Anti-human lymphotoxin alpha antibodies, compositions, methods and uses |
| 09/13/2006 | EP1699485A2 Anti-hydroxylase antibodies and uses thereof |
| 09/13/2006 | EP1699484A2 Humanized antibodies against vascular endothelial growth factor |
| 09/13/2006 | EP1699483A1 Combination vaccine for poultry |
| 09/13/2006 | EP1699482A2 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability |
| 09/13/2006 | EP1699481A2 Methods and compositions comprising bacteriophage nanoparticles |
| 09/13/2006 | EP1699480A1 Allogeneic tumor therapeutic agent |
| 09/13/2006 | EP1699479A1 Synthetic protein as tumor-specific vaccine |
| 09/13/2006 | EP1699460A2 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
| 09/13/2006 | EP1385452B1 Ophthalmic drug delivery device |
| 09/13/2006 | EP1284720B1 L-fmau for the treatment of hepatitis delta viral infection |
| 09/13/2006 | EP1280828B1 Anthrax-specific antigen, vaccines comprising said antigen, anthrax-specific antibodies, and their uses |
| 09/13/2006 | EP1196579B1 Tryptase inhibitor |
| 09/13/2006 | EP1165126B1 Process for preparing a human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 09/13/2006 | EP1163272B1 Antibodies specific for cyp1b1 |
| 09/13/2006 | EP1140158B1 Multi-component vaccine comprising at least two antigens from haemophilus influenzae |
| 09/13/2006 | EP1095062B1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 09/13/2006 | EP1064025B1 Combined vaccine compositions |
| 09/13/2006 | EP0832093B1 Expression of lipoproteins |
| 09/13/2006 | EP0811065B1 Antagonists of interleukin-15 |
| 09/13/2006 | CN1833027A Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| 09/13/2006 | CN1832969A Etherified carbamate functional copolymers of isobutylene type monomers, and their use in curable compositions |
| 09/13/2006 | CN1832965A Endothelial cell specific antibodies and uses thereof |
| 09/13/2006 | CN1832964A Method of detecting probnp with a monoclonal antibody binding to the amino acids 41-46 |
| 09/13/2006 | CN1832756A Method of altering the binding specificity of proteins by oxidation-reduction reactions |
| 09/13/2006 | CN1831011A Antigen epitope of beta2-microglobulin and its application |
| 09/13/2006 | CN1831009A Prawn white-spots syndrom virus (WSSV) membrane protein and its antibody |
| 09/13/2006 | CN1830489A Tumour polypeptide vaccine based on gastrin release peptide |
| 09/13/2006 | CN1275041C Prognostic indicator |
| 09/13/2006 | CN1274707C Nucleotide specific for escherichia coli 0159 O-antigen |
| 09/13/2006 | CN1274364C Crosslinker of anti-FcªŠRIª‡ monoclonal antibody Fab and tripterine |
| 09/13/2006 | CN1274235C Anti-dental caries chewing gum and preparation |
| 09/12/2006 | US7105656 Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| 09/12/2006 | US7105655 Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain |
| 09/12/2006 | US7105649 Gene and amplification with polynucleotides having amino acid sequence |
| 09/12/2006 | US7105641 Immunoglobulin for binding monocyte chemoattractant protein-1(MCP-1) and preventing and/or treating atherosclerosis and cancer ; antitumor agents |
| 09/12/2006 | US7105574 Composition of GAP DMORIE and colipids; adjuvant of cytofectin and neutral lipid such as a phosphatidylethanolamine provide elevation of antibody levels particularly in applications where antibody levels from the immunogen-encoding polynucleotide alone are sub-optimal |
| 09/12/2006 | US7105495 Method according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications |
| 09/12/2006 | US7105484 GDNF receptorα |
| 09/12/2006 | US7105333 Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
| 09/12/2006 | US7105330 Immunoglobulin for detection and isolation of preferential glycosidase; tumor diagnosis and antitumor agents |
| 09/12/2006 | US7105317 Immunogenic compositions comprising vrg-gene products from Bordetella extracts |